This preprint is under consideration at World Journal of Surgical Oncology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Perivascular epitheloid cell tumor (PEComas) are characterised by expression of both muscles, most often smooth muscle actin (in ~80% of cases) and melanocytic markers (mainly HMB-45 and Melan A). TFE 3 associated PEComas are new variant which are poorly defined due to their limited reports in literature. These tumors lack response to targeted mTOR inhibitor therapy due to lack of mutation in TSC gene. Hereby we are reporting a case of TFE3 associated pelvic PEComa showing excellent response to Everolimus.
Case presentation: A 45-year-old female presented with complaint of abdominal mass and bleeding per vaginum for 4 months. She had a history of total abdominal hysterectomy 3 years back in view of abnormal uterine bleeding and exploratory laprotomy 7 months back to remove some pelvic mass. Imaging suggested of ill-defined heterogenous mass of 9.3 x 9.2 x 16 cm involving uterus, cervix and upper 1/3 vagina. Multiple omental and peritoneal deposits were also seen, making probable diagnosis of carcinoma endometrium. USG guided biopsy showed cores of fibrous tissue with presence of cells in sheets with granular eosinophillic cytoplasm, IHC showed positivity for TFE -3, H Caldesmon, GATA-3, Melan A-and HMB-45, Ki 67 index was 35%. On the basis of above diagnosis of PEComa was made and she was started on Everolimus, repeat imaging after 3 months of therapy, showed complete response.
Conclusion: We are reporting first case of malignant pelvic TFE 3 PEComa showing response to mTOR therapy. Identification of TFE 3 PEComa is important because they showed different biologic behaviour then their conventional PEComa.
Keywords
Perivascular epitheliod cell tumor, Mtor Therapy, TFE3 , PEComa, uterus, Gynecological
Figure 1
Figure 2
Figure 3
Figure 4
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 23 Sep, 2021
No community comments so far
Editorial decision: Minor Revision
On 21 Oct, 2021
Reviewer #5 agreed
On 02 Oct, 2021
Reviewer #4 agreed
On 01 Oct, 2021
Reviews received
Received 01 Oct, 2021
Reviewer #3 agreed
On 30 Sep, 2021
Reviewer #2 agreed
On 29 Sep, 2021
Reviewer #1 agreed
On 29 Sep, 2021
Reviewers invited
Invitations sent on 21 Sep, 2021
Editor assigned
On 20 Sep, 2021
Submission checks complete
On 19 Sep, 2021
Editor invited
On 19 Sep, 2021
First submitted
On 16 Sep, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
Learn more about our company.
This preprint is under consideration at World Journal of Surgical Oncology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 23 Sep, 2021
No community comments so far
Editorial decision: Minor Revision
On 21 Oct, 2021
Reviewer #5 agreed
On 02 Oct, 2021
Reviewer #4 agreed
On 01 Oct, 2021
Reviews received
Received 01 Oct, 2021
Reviewer #3 agreed
On 30 Sep, 2021
Reviewer #2 agreed
On 29 Sep, 2021
Reviewer #1 agreed
On 29 Sep, 2021
Reviewers invited
Invitations sent on 21 Sep, 2021
Editor assigned
On 20 Sep, 2021
Submission checks complete
On 19 Sep, 2021
Editor invited
On 19 Sep, 2021
First submitted
On 16 Sep, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Perivascular epitheloid cell tumor (PEComas) are characterised by expression of both muscles, most often smooth muscle actin (in ~80% of cases) and melanocytic markers (mainly HMB-45 and Melan A). TFE 3 associated PEComas are new variant which are poorly defined due to their limited reports in literature. These tumors lack response to targeted mTOR inhibitor therapy due to lack of mutation in TSC gene. Hereby we are reporting a case of TFE3 associated pelvic PEComa showing excellent response to Everolimus.
Case presentation: A 45-year-old female presented with complaint of abdominal mass and bleeding per vaginum for 4 months. She had a history of total abdominal hysterectomy 3 years back in view of abnormal uterine bleeding and exploratory laprotomy 7 months back to remove some pelvic mass. Imaging suggested of ill-defined heterogenous mass of 9.3 x 9.2 x 16 cm involving uterus, cervix and upper 1/3 vagina. Multiple omental and peritoneal deposits were also seen, making probable diagnosis of carcinoma endometrium. USG guided biopsy showed cores of fibrous tissue with presence of cells in sheets with granular eosinophillic cytoplasm, IHC showed positivity for TFE -3, H Caldesmon, GATA-3, Melan A-and HMB-45, Ki 67 index was 35%. On the basis of above diagnosis of PEComa was made and she was started on Everolimus, repeat imaging after 3 months of therapy, showed complete response.
Conclusion: We are reporting first case of malignant pelvic TFE 3 PEComa showing response to mTOR therapy. Identification of TFE 3 PEComa is important because they showed different biologic behaviour then their conventional PEComa.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...